Trial Profile
Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation with postponed donor lymphocyte infusion in elderly acute myeloid leukemia and high risk myelodysplasia patients
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Nov 2014
Price :
$35
*
At a glance
- Drugs Amsacrine (Primary) ; Cytarabine (Primary) ; Fludarabine (Primary) ; Alemtuzumab; Antithymocyte globulin; T cell replacement therapy
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms FLAMSA-TCD-NMA-AlloSCT
- 01 Jul 2013 New trial record